<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970943</url>
  </required_header>
  <id_info>
    <org_study_id>AT007530-01</org_study_id>
    <secondary_id>R21AT007530-01</secondary_id>
    <nct_id>NCT01970943</nct_id>
  </id_info>
  <brief_title>Molecular and Functional PET-fMRI Measures of Analgesia in Migraine</brief_title>
  <official_title>Molecular and Functional PET-fMRI Measures of Analgesia in Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The placebo effect is a phenomenon that has experienced major advances of its understanding
      in the last decade. However, mechanisms of placebo analgesia in chronic pain patients have
      yet to be compared to healthy subjects. The investigators study aims to investigate the
      magnitude of placebo response and related opioid release in patients that suffer from
      episodic migraines as compared to healthy controls. In particular, the investigators are
      looking to map brain activity during placebo analgesia using modern brain imaging techniques
      such as functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET).
      The investigators hypothesis is that placebo response and the availability of opioid
      receptors is reduced in chronic migraine patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2012</start_date>
  <completion_date type="Actual">October 30, 2017</completion_date>
  <primary_completion_date type="Actual">April 30, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale (VAS) 0-10 Pain Rating</measure>
    <time_frame>1 day</time_frame>
    <description>This study will investigate how placebo may reduce experimental pain induced by contact heat.
Patients rate heat stimulus intensity on a 0-10 scale, where 0 is no pain, and 10 is most intense pain possible. Data is reported to the placebo condition.
The Visual Analogue Scale (VAS) consists of a straight line with the endpoints defining extreme limits such as 'no pain at all' and 'most intense pain possible'. The patient is asked to mark his pain level on the line between the two endpoints.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Anticipation fMRI BOLD Signal</measure>
    <time_frame>1 day</time_frame>
    <description>We imaged the subjects under an MRI scan. All data was collected on a Siemens 3 Tesla MR scanner using a PETcompatible eight-channel head coil. Structural T1 weighted MPRAGE Functional scans were preprocessed using slice timing correction, realignment, normalization, and smoothing (8 mm FWHM Gaussian filter), using SPM12. In each condition (placebo &amp; no drug) subjects underwent four sets of pain anticipation at high and low temperatures (somatosensory control condition). The stimuli were modeled as boxcar time series, with additional regressors for temperature ramp-up, ramp-down, pain rating sequence, and six motion regressors.data were collected for each of the two PET-MR scans. Contrasts analyzed included pain anticipation.
The values for the 8 sets of anticipation, for both the migraine and the healthy group are combined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Stimulation fMRI BOLD Signal</measure>
    <time_frame>1 day</time_frame>
    <description>We imaged the subjects under an MRI scan. All data was collected on a Siemens 3 Tesla MR scanner using a PETcompatible eight-channel head coil. Structural T1 weighted MPRAGE Functional scans were preprocessed using slice timing correction, realignment, normalization, and smoothing (8 mm FWHM Gaussian filter), using SPM12. In each condition (placebo &amp; no drug) subjects underwent four sets of pain stimulation at high and low temperatures (somatosensory control condition). The stimuli were modeled as boxcar time series, with additional regressors for temperature ramp-up, ramp-down, pain rating sequence, and six motion regressors.data were collected for each of the two PET-MR scans. Contrasts analyzed included pain stimulation.
The values for the 8 sets of stimulation, for both the migraine and the healthy group are combined</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET Diprenorphine</measure>
    <time_frame>1 day</time_frame>
    <description>We sought to find if endogenous opioid levels and endogenous opioid release induced by placebo administration differentiates between the no intervention first, then placebo group compared to the placebo first, then no intervention group in migraine patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Migraine</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>No Intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Injection (Placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PET-fMRI investigation on healthy subjects and patients with migraine. Placebo condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be compared to No Intervention.</description>
    <arm_group_label>Saline Injection (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Migraine patients with aura with acute episodic migraine meeting the IHS
             Classification ICHD-II criteria, 3-14 migraines per month.

          -  History of episodic migraine for at least 3 years

          -  Ages 21-50

          -  Male or Female

          -  Right Handed

        Matched healthy subjects will also be recruited.

        Exclusion Criteria:

          -  Other significant disease (systemic or CNS)

          -  Pregnancy

          -  Claustrophobia

          -  Weight &gt;235 lbs (limit of MRI table)

          -  Significant drug including alcohol history (&gt; 7 glasses of alcohol per week)

          -  Beck Depression Inventory II (BDI-II) score &gt; 25 (moderate to severe depression)

          -  Any metal implants incompatible with MRI (including dental bridges, crowns, retainers,
             orthodontic devices e.g. braces, IUDs, aneurysm clips or other devices, tattoos
             containing metallic ink, cardiac pacemakers, prosthetic hear valves, other prostheses,
             neurostimulator devices, implanted infusion pumps, exposure to shrapnel or metal
             filings, cochlear implants, etc.)

          -  Previous significant research related exposure to ionizing radiation.

          -  History of allergy or adverse reaction to opioids

          -  Significant medical history of such as seizure disorder, diabetes, alcoholism, cardiac
             disease including coronary artery disease, psychiatric problems; drug addiction,
             respiratory problems, liver disease, etc.

          -  Positive drug of abuse screen (excluding medications currently prescribed for their
             clinical condition, e.g. opioids, benzodiazepines, etc.)

          -  Patients with migraine &lt;72 hours prior to the experiments will not be included to
             ensure inter-ictal state.

          -  Opioids or preventative medication such as topiramate, SSRIs etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Borsook, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Childrenâ€™s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Athinoula A. Martinos. Center for Biomedical Imaging</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 23, 2013</study_first_submitted>
  <study_first_submitted_qc>October 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2013</study_first_posted>
  <results_first_submitted>December 1, 2015</results_first_submitted>
  <results_first_submitted_qc>May 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2019</results_first_posted>
  <last_update_submitted>May 15, 2019</last_update_submitted>
  <last_update_submitted_qc>May 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>David Borsook</investigator_full_name>
    <investigator_title>David Borosook, MD</investigator_title>
  </responsible_party>
  <keyword>migraine, headache, episodic, chronic, pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study design was indeed crossover, but the cross-over was done immediately on the same day. In other words, participants were either scheduled to receive no intervention, and then placed placebo approximately 2 hours later to allow for washout. Or placed placebo first, and then no intervention approximately 2 hours later. No actual drug used.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>No Intervention First, Then Placebo</title>
          <description>PET-fMRI investigation on healthy subjects and patients with migraine. No drug conditioning and then placebo saline injection.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then No Intervention</title>
          <description>PET-fMRI investigation on healthy subjects and patients with migraine. Placebo saline injected followed by no drug conditioning.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>healthy subjects and patients with migraine</population>
      <group_list>
        <group group_id="B1">
          <title>No Intervention</title>
          <description>PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition and placebo (saline IV injection)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Analogue Scale (VAS) 0-10 Pain Rating</title>
        <description>This study will investigate how placebo may reduce experimental pain induced by contact heat.
Patients rate heat stimulus intensity on a 0-10 scale, where 0 is no pain, and 10 is most intense pain possible. Data is reported to the placebo condition.
The Visual Analogue Scale (VAS) consists of a straight line with the endpoints defining extreme limits such as 'no pain at all' and 'most intense pain possible'. The patient is asked to mark his pain level on the line between the two endpoints.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No Intervention</title>
            <description>PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition and placebo saline injection.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>PET-fMRI investigation on healthy subjects and patients with migraine. Placebo saline injection followed by no drug condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale (VAS) 0-10 Pain Rating</title>
          <description>This study will investigate how placebo may reduce experimental pain induced by contact heat.
Patients rate heat stimulus intensity on a 0-10 scale, where 0 is no pain, and 10 is most intense pain possible. Data is reported to the placebo condition.
The Visual Analogue Scale (VAS) consists of a straight line with the endpoints defining extreme limits such as 'no pain at all' and 'most intense pain possible'. The patient is asked to mark his pain level on the line between the two endpoints.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.4"/>
                    <measurement group_id="O2" value="7.2" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Anticipation fMRI BOLD Signal</title>
        <description>We imaged the subjects under an MRI scan. All data was collected on a Siemens 3 Tesla MR scanner using a PETcompatible eight-channel head coil. Structural T1 weighted MPRAGE Functional scans were preprocessed using slice timing correction, realignment, normalization, and smoothing (8 mm FWHM Gaussian filter), using SPM12. In each condition (placebo &amp; no drug) subjects underwent four sets of pain anticipation at high and low temperatures (somatosensory control condition). The stimuli were modeled as boxcar time series, with additional regressors for temperature ramp-up, ramp-down, pain rating sequence, and six motion regressors.data were collected for each of the two PET-MR scans. Contrasts analyzed included pain anticipation.
The values for the 8 sets of anticipation, for both the migraine and the healthy group are combined</description>
        <time_frame>1 day</time_frame>
        <population>9 migraine subjects</population>
        <group_list>
          <group group_id="O1">
            <title>No Intervention</title>
            <description>PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition and placebo saline injection.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>PET-fMRI investigation on healthy subjects and patients with migraine. Placebo saline injection followed by no drug condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Anticipation fMRI BOLD Signal</title>
          <description>We imaged the subjects under an MRI scan. All data was collected on a Siemens 3 Tesla MR scanner using a PETcompatible eight-channel head coil. Structural T1 weighted MPRAGE Functional scans were preprocessed using slice timing correction, realignment, normalization, and smoothing (8 mm FWHM Gaussian filter), using SPM12. In each condition (placebo &amp; no drug) subjects underwent four sets of pain anticipation at high and low temperatures (somatosensory control condition). The stimuli were modeled as boxcar time series, with additional regressors for temperature ramp-up, ramp-down, pain rating sequence, and six motion regressors.data were collected for each of the two PET-MR scans. Contrasts analyzed included pain anticipation.
The values for the 8 sets of anticipation, for both the migraine and the healthy group are combined</description>
          <population>9 migraine subjects</population>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5665" spread="0.8318"/>
                    <measurement group_id="O2" value="1.1743" spread="0.8447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6078</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Stimulation fMRI BOLD Signal</title>
        <description>We imaged the subjects under an MRI scan. All data was collected on a Siemens 3 Tesla MR scanner using a PETcompatible eight-channel head coil. Structural T1 weighted MPRAGE Functional scans were preprocessed using slice timing correction, realignment, normalization, and smoothing (8 mm FWHM Gaussian filter), using SPM12. In each condition (placebo &amp; no drug) subjects underwent four sets of pain stimulation at high and low temperatures (somatosensory control condition). The stimuli were modeled as boxcar time series, with additional regressors for temperature ramp-up, ramp-down, pain rating sequence, and six motion regressors.data were collected for each of the two PET-MR scans. Contrasts analyzed included pain stimulation.
The values for the 8 sets of stimulation, for both the migraine and the healthy group are combined</description>
        <time_frame>1 day</time_frame>
        <population>9 migraine subjects</population>
        <group_list>
          <group group_id="O1">
            <title>No Intervention</title>
            <description>PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition and placebo saline injection.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>PET-fMRI investigation on healthy subjects and patients with migraine. Placebo saline injection followed by no drug condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Stimulation fMRI BOLD Signal</title>
          <description>We imaged the subjects under an MRI scan. All data was collected on a Siemens 3 Tesla MR scanner using a PETcompatible eight-channel head coil. Structural T1 weighted MPRAGE Functional scans were preprocessed using slice timing correction, realignment, normalization, and smoothing (8 mm FWHM Gaussian filter), using SPM12. In each condition (placebo &amp; no drug) subjects underwent four sets of pain stimulation at high and low temperatures (somatosensory control condition). The stimuli were modeled as boxcar time series, with additional regressors for temperature ramp-up, ramp-down, pain rating sequence, and six motion regressors.data were collected for each of the two PET-MR scans. Contrasts analyzed included pain stimulation.
The values for the 8 sets of stimulation, for both the migraine and the healthy group are combined</description>
          <population>9 migraine subjects</population>
          <units>arbitrary units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".5745" spread=".8224"/>
                    <measurement group_id="O2" value="1.1537" spread=".8326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PET Diprenorphine</title>
        <description>We sought to find if endogenous opioid levels and endogenous opioid release induced by placebo administration differentiates between the no intervention first, then placebo group compared to the placebo first, then no intervention group in migraine patients.</description>
        <time_frame>1 day</time_frame>
        <population>9 migraine subjects</population>
        <group_list>
          <group group_id="O1">
            <title>No Intervention</title>
            <description>PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition and placebo saline injection.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>PET-fMRI investigation on healthy subjects and patients with migraine. Placebo saline injection followed by no drug condition.</description>
          </group>
        </group_list>
        <measure>
          <title>PET Diprenorphine</title>
          <description>We sought to find if endogenous opioid levels and endogenous opioid release induced by placebo administration differentiates between the no intervention first, then placebo group compared to the placebo first, then no intervention group in migraine patients.</description>
          <population>9 migraine subjects</population>
          <units>standard uptake value</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.251" spread="0.259"/>
                    <measurement group_id="O2" value="1.214" spread="0.175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.037786</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>No Intervention</title>
          <description>PET-fMRI investigation on healthy subjects and patients with migraine. No drug condition.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>PET-fMRI investigation on healthy subjects and patients with migraine. Placebo saline injection.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr David Borsook, study PI</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>6172817135</phone>
      <email>david.borsook@childrens.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

